FDA Agrees to Modified Endpoints for Seelos Therapeutics Phase III Trial of SLS002 for Acute Suicidal Ideation and Behavior
Seelos Therapeutics, a biopharmaceutical company in the clinical stage, has recently received the minutes from its End of Phase II ...
